Assenagon Asset Management S.A. Design Therapeutics, Inc. Transaction History
Assenagon Asset Management S.A.
- $54.8 Billion
- Q1 2025
A detailed history of Assenagon Asset Management S.A. transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 36,917 shares of DSGN stock, worth $140,653. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,917
Previous 56,617
34.8%
Holding current value
$140,653
Previous $349,000
59.31%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding DSGN
# of Institutions
101Shares Held
33.4MCall Options Held
4KPut Options Held
3.1K-
Sr One Capital Management, LP6.53MShares$24.9 Million11.4% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$16.1 Million3.17% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$8.78 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$7.44 Million0.47% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.82MShares$6.93 Million0.02% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $213M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...